找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Mechanisms of Drug Resistance in Cancer Therapy; Mario Mandalà,Emanuela Romano Book 2018 Springer Nature Switzerland AG 2018 Drug resistan

[復(fù)制鏈接]
樓主: 非決定性
21#
發(fā)表于 2025-3-25 06:10:37 | 只看該作者
Mechanisms of Resistance in Multiple Myeloma,medullary sites. Multi-modality approaches including “novel agents,” traditional chemotherapy, and/or stem cell transplantation are used in MM therapy. Drug resistance, however, ultimately develops and the disease remains incurable for the vast majority of patients. In this chapter, we review both t
22#
發(fā)表于 2025-3-25 09:33:20 | 只看該作者
23#
發(fā)表于 2025-3-25 14:15:05 | 只看該作者
Mario Mandalà,Emanuela RomanoGives an updated overview on the possible reasons of failure of new and promising therapeutic opportunities.Provides extensive discussions of issues including pharmacodynamic and pharmacokinetic mecha
24#
發(fā)表于 2025-3-25 16:00:36 | 只看該作者
Handbook of Experimental Pharmacologyhttp://image.papertrans.cn/m/image/628714.jpg
25#
發(fā)表于 2025-3-25 21:46:56 | 只看該作者
https://doi.org/10.1007/978-3-030-10507-5Drug resistance; Drug mechanisms; Targeted therapy; Immunotherapy; Chemotherapy; antibacterial drug resis
26#
發(fā)表于 2025-3-26 01:00:23 | 只看該作者
Springer Nature Switzerland AG 2018
27#
發(fā)表于 2025-3-26 06:31:37 | 只看該作者
28#
發(fā)表于 2025-3-26 12:01:27 | 只看該作者
Book 2018 rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments. It offers to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities..
29#
發(fā)表于 2025-3-26 13:25:49 | 只看該作者
Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival,research have suggested that the intrinsic pro-survival signaling crosstalk is the driving force in acquired resistance to a targeted therapy, which may be abolished by interfering with the cross-reacting network.
30#
發(fā)表于 2025-3-26 20:24:37 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-16 13:24
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
南宁市| 华池县| 兴义市| 大化| 万山特区| 汤原县| 庆安县| 凭祥市| 南陵县| 界首市| 斗六市| 靖西县| 镇安县| 通城县| 安图县| 苍溪县| 林西县| 天全县| 安徽省| 得荣县| 怀仁县| 沅江市| 绥阳县| 安国市| 嵊州市| 梅州市| 华池县| 泽普县| 乌拉特后旗| 澜沧| 新昌县| 泗阳县| 汉川市| 蓝山县| 惠东县| 兴宁市| 梓潼县| 昌江| 大方县| 汝南县| 新龙县|